Here’s what you’ll learn when you read this article: ActRIIA/B inhibition shows promise in preserving lean muscle during rapid weight loss, unlike GLP-1 drugs alone. New therapies like LAE102 and dual ligand blockers…
Here’s what you’ll learn when you read this article: GLP‑1 and dual agonist drugs like tirzepatide have shown the ability to slow tumor growth in obesity‑linked cancers, especially in preclinical models. Early human…
Here’s what you’ll learn when you read this article: The FDA removed black box warnings for most systemic HRT products in late 2025, reshaping menopause care. Timing of therapy initiation now plays a…
How the 2025 Expert Consensus and MENO‑ABC Trial Challenge Old Rules Here’s what you’ll learn when you read this article: The 2025 expert consensus opens the door to case-by-case HRT use in low-risk…
Takeaways FGF21 and GDF15 analogs offer distinct mechanisms beyond GLP-1 for treating obesity and metabolic disease. Late-stage trials show promising effects on liver fat, appetite control, and thermogenesis with fewer GI side effects.…